Results 181 to 190 of about 2,327,860 (219)

Anaphylactoid reaction to recombinant tissue plasminogen activator

European Journal of Emergency Medicine, 2007
Anaphylactoid reaction to recombinant tissue plasminogen activator for the thrombolytic treatment of acute ischemic stroke is an uncommon complication. An increased risk of anaphylaxis may be found in patients concomitantly being treated with angiotensin-converting enzyme inhibitors, as illustrated by this case report describing a patient who ...
Kristina R. Krmpotic, Christopher M.B. Fernandes   +1 more
openaire   +1 more source

Recombinant Tissue Plasminogen Activator (rtPA) for Stroke

The Neurologist, 2005
To review the 8-year experience with recombinant tissue plasminogen activator (rtPA) for stroke, with commentary on ramifications for the approach to stroke treatment, directions in stroke research, and sociological aspects of stroke as a disease of concern in our society.Approved in 1996, rtPA remains the only drug indicated for the treatment of ...
openaire   +2 more sources

Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance

Pediatric Nephrology, 2005
Hemodialysis (HD) catheter occlusion is a common cause of poor blood flow and inadequate dialysis. In order to address this problem in our pediatric dialysis unit, we elected to use short (2-h) infusions of low-dose recombinant tissue plasminogen activator (rtPA) for thrombolysis of occluded catheters.
Oluwatoyin F, Bamgbola, Marcela, del Rio, Frederick J, Kaskel, Joseph T, Flynn   +3 more
openaire   +2 more sources

The Effect of Various Contrast Media on the Activation of Plasminogen by Streptokinase or Recombinant Tissue Plasminogen Activator In Vitro

Investigative Radiology, 1994
Radiologic contrast media (CM) may influence processes of coagulation and fibrinolysis. In the current study, the effects of various CM on the formation of plasmin were examined in an in vitro buffer system.The effects of three clinically relevant concentrations of seven different iodine-containing CM and gadolinium-DTPA on streptokinase (SK) or ...
A, Schilvold, S, Bjørnsen, C, Ing, F, Brosstad   +3 more
openaire   +2 more sources

Recombinant tissue plasminogen activator.

Neonatal network : NN, 1996
The widespread use of indwelling intravascular catheters, such as central venous lines and umbilical vessel catheters, has resulted in an increased number of thrombotic complications and subsequently a growing need for specific thrombolytic therapy.
openaire   +1 more source

Role of Recombinant Tissue Plasminogen Activator in Free Flap Salvage

Journal of Reconstructive Microsurgery, 2006
The use of recombinant tissue plasminogen activator (rTPA) in microvascular surgery has been previously reported, but no consensus exists regarding its indications, dose, efficacy, or safety. The records of all patients undergoing free tissue transfer at one institution between 2000 and 2005 were reviewed.
Brian D, Rinker, Daniel H, Stewart, Lee L Q, Pu, Henry C, Vasconez   +3 more
openaire   +2 more sources

Recombinant Tissue Plasminogen Activator for Prosthetic Mitral-Valve Thrombosis

New England Journal of Medicine, 1995
To the Editor: The reported incidence of thrombosis of prosthetic mitral or aortic valves ranges from 0.03 to 4.3 percent per year.1 Thrombectomy or valve replacement is the conventional treatment ...
D, Astengo, L, Badano, D, Bertoli
openaire   +2 more sources

Stability of Recombinant Tissue Plasminogen Activator

American Journal of Ophthalmology, 1989
G J, Jaffe, G D, Green, G W, Abrams
openaire   +2 more sources

Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator?

Annals of Internal Medicine, 1990
In patients with acute myocardial infarction, intravenous streptokinase therapy recanalizes 40% to 45% of occluded coronary arteries and reduces mortality by 25%. Recombinant tissue-type plasminogen activator (rt-PA) therapy is more potent for coronary arterial thrombolysis, producing both more rapid and more frequent (65% to 70%) reperfusion.
openaire   +2 more sources

Recombinant Tissue-Type Plasminogen Activator

1991
D, Collen, W F, Bennett
openaire   +2 more sources